PLRX Pliant Therapeutics, Inc.
Stock Price & Overview

$1.380.01 (+0.73%)4:00 PM 05/16/25
NASDAQ | $USD | Post-Market: $1.38 7:59 PM

PLRX Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Latest Headlines

Ratings Summary

People Also Follow

Similar to PLRX

ETFs Holding PLRX

PLRX Company Profile

Pliant Therapeutics, Inc. logo
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Employees
171
Founded
2015
Address
  • 331 Oyster Point Boulevard
  • South San Francisco, CA, 94080
  • United States
Phone Number
650 481 6770

PLRX Revenue

PLRX Earnings Per Share

Earnings Estimates

Earnings Revisions

Valuation

Growth

Profitability

Momentum

Capital Structure

Dividends

PLRX does not currently pay a dividend.

PLRX Ownership

PLRX Peers

Risk

Technicals

Investor Presentations

PLRX SEC Filings

PLRX Income Statement

PLRX Balance Sheet

PLRX Cash Flow Statement

PLRX Long Term Solvency

Discover More

You may be interested in:

Pliant Therapeutics, Inc. (PLRX) Frequently Asked Questions